NEW YORK – In an expansion cohort of the Phase I PROFILE 1001 trial, 32 percent of advanced non-small cell lung cancer patients with MET exon 14 alterations saw their tumors shrink when treated with crizotinib (Pfizer's Xalkori).
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.
This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.